Tumor Profiling in the NGS Era

Speaker:
Gerald Goh
Senior Regional Segment Marketing Manager,
Illumina Asia Pacific Japan

Biography:
Dr. Gerald Goh has 10+ years of research experience in using genetics to understand the biology and underlying mechanisms of various human diseases, from autism to cancer. His career in oncology research began with the use of exome sequencing for the identification of driver genes in a variety of human cancers, using some of the first whole-exome capture arrays to interrogate the mutational landscape in these cancers. His work with numerous key opinion leaders around the world has resulted in over 25 peer-reviewed publications in high-impact journals including Nature Genetics. Prior to joining Illumina, Gerald was part of the business development team at the Genome Institute of Singapore, stimulating research collaborations and industry partnerships in oncology. His current focus is on driving momentum in next-generation sequencing applications across the cancer continuum, from basic research to clinical testing. Gerald received his PhD in Genetics from Yale University and holds a Bachelor of Arts degree in Biological Sciences from the University of Chicago.

NGS for Cancer Testing: A Practical Perspective

Speaker:
Joel Geoghegan
Associate Manager, Sales Specialist (Oncology),
Illumina Asia Pacific Japan

Biography:
Joel Geoghegan leads a team of Illumina Oncology Specialists in the Asia-Pacific region to help drive the adoption of next-generation sequencing technology across the cancer continuum supporting basic cancer research, translational research and oncology testing. His career spans 20+ years of developing and implementing cutting edge genomic technologies in research and clinical settings. In his previous role with SA Pathology (Adelaide, South Australia), he supervised the first lab in Australia to receive ISO13485 accreditation for diagnostic whole exome sequencing, transcriptome sequencing and somatic variant detection.

Before moving to Australia, he was based in Madison, WI, USA as a Product Development Scientist for NimbleGen Systems (later Roche NimbleGen through acquisition) overseeing the launch of numerous high-density array and hybridisation-based enrichment products. His career began with 2 fellowships at the National Cancer Institute (NCI) in Bethesda, MA, USA using some of the first custom microarrays to study gene expression changes associated with the progression of cancers. He later transitioned to a new role in the Advanced Technology Center for the NCI manufacturing, developing and training researchers how to use microarrays for gene expression and comparative genomic hybridization. His focus and expertise in new technologies has led to numerous collaborations with key opinion leaders around the world resulting in publications in Nature Genetics, Nature Methods, PNAS and Human Mutation to name a few.

Tertiary Analysis Support in Clinical Reporting

Speaker:
Jaya Singh
Associate Director-Business Development,
Strand Life Sciences, India

Biography:
Dr. Jaya Singh has a Ph.D. in (Biochemistry) from Lucknow University, focused on prevention of skin tumour development in mouse skin by natural anticancer drugs and their mode of action. Based on her thesis work; she got a US Patent- on “Pharmaceutical composition for the management of tumors" in 2009 (#US 7655678 B2). She has published many papers in reputed international journals. After Ph.D., she went to US for a postdoctoral training in the University of Kentucky on subjects related to DNA Damage and Repair, Cancer selective apoptosis and molecular oncology. At Strand, Jaya has worked on Skin pathway models, microarray data analysis, data mining and clinical reporting. Currently, she is involved in the global business development for variant science.

Q & A Session / Panel Discussion